S tandard measurement of symptoms and function in schizophrenia patients is crucial for research and practice. Numerous instruments have been developed; however, their use has been limited to the research context. 1 Limitations to their use in clinical practice include: time constraints, difficulties for standardized administration, as well as for their analysis and interpretation. 2 A recent review proposed the use of very short versions of well-established instruments for assessing symptomatic remission in clinical practice, emphasizing both attenuation and disappearance of symptoms and stability in that clinical situation. 3 This proposal might help overcome most of the difficulties in using standardized symptoms instruments in the evaluation of schizophrenia patients in routine clinical care.
Method

Patients
The performance of the SF of the SAPS and SANS was compared with the standard forms in a multicentre, randomized, open-label, 1-year clinical trial of Spanish outpatients with schizophrenia (DSM-IV criteria) with prominent negative symptoms (SANS summary score >10). 4, 5 Patients were evaluated at baseline, with 6-and 12-month follow-ups. Baseline data was available for 235 patients, and complete follow-up data for 159 patients. Data collection took place in 2001 and 2002, and details can be found elsewhere. 6 Assessments included the standard SANS, SAPS, and the CGI-S, which is a reliable and valid measure of severity of illness and the degree of change in severity. 7 Permission for use of the scales were obtained by the clinical trial promotors.
SAPS and SANS: Standard and Short Forms
The standard SAPS provides clinically relevant information on positive and disorganization symptoms. We used the 30-item version, which is organized in 4 domains. A composite SAPS score (ranging from 0 = best, to 150 = worst) was calculated. The standard SANS used in our study includes a total of 20 items in 5 domains. Also a composite SANS score (ranging from 0 = best, to 100 = worst) was calculated. An overall score was calculated as the sum of the 2 composite scores. As proposed by Andreasen et al, 3 the SFs included only 4 items for each scale: 7, 20, 25, and 34 for the SAPS-SF and 7, 13, 17, and 22 for the SANS-SF. A composite score for each SF (range 0 to 20) and an overall SF score (range 0 to 40) were calculated. This information is summarized in Table 1 . The SAPS and the SANS are proprietary measures. 4, 5 Remission Following the proposal made by the working group's consensus on remission of schizophrenia, we defined remission based on 2 considerations: severity and duration. Concerning severity, a score of mild or less (scores £2) on all items is considered representative of an impairment level consistent with symptomatic remission of illness. Concerning duration, given the long-term course of the disorder, the group proposed that this situation should last at least 6 months. Therefore, maximum possible scores were 40 for standard SAPS, 60 for standard SANS, and 16 for the overall SF score. 3
Analysis
Reliability of the SFs of the SAPS and SANS was assessed through the Cronbach's alpha coefficient. Validity was assessed computing the cross-sectional Pearson's r correlation coefficient among the short and the standard form scores, and also the correlations with the CGI-S. Longitudinal analyses included the correlation between the 0-to 12-month change scores in the short and standard forms, as well as the sensitivity and specificity of the SFs in assessing remission, taking the standard forms as the gold standard of remission. Agreement in the assessment of remission was measured using the kappa coefficient. 8
Results
A total of 235 patients were analyzed. Overall mean age was 36.3 years, SD 10.5. Almost two-thirds of the patients were men (72.4%) and all of them were in treatment. Cronbach's alpha coefficients were 0.78 for the SAPS-SF and 0.72 for the SANS-SF composite scores, and 0.78 for the SF overall score. The SF overall score correlated 0.89 with that of the standard form and 0.47 with the CGI (the correlation of the standard forms with the CGI was 0.45).
The 0-to 12-month change in SF overall score correlated 0.89, with the change overall score of the standard form. The SFs identified 36 patients that had remitted according to the standard SAPS and SANS (see Table 2 ). When using the preestablished cut-off point of £16 for the overall SF score, sensitivity was 100% (95%CI, 90.3% to 100%), specificity was 71.5% (95%CI, 62.7% to 79.5%), and the kappa was 0.53 (95%CI, 0.40 to 0.67).
The AUC analysis yielded a value of 0.94 (95%CI, 0.91 to 0.97). With the cut-off point of overall SF score as 8, a sensitivity of 86.1%, specificity of 86.2, and a good agreement with the standard SPAS and SANS overall score (k = 0.65) were obtained.
Discussion
Formal assessment of remission in schizophrenia is a crucial outcome both for clinical research and for practice. Such measurement is carried out only in research settings owing to the burden in administration, and difficulties scoring and interpreting the results. We have established acceptable reliability and preliminary validity of the recently proposed short forms of the SAPS and SANS (8 items in total). Our results represent a potentially important contribution in supporting the use of this short form in the routine evaluation of schizophrenia outpatients.
Two limitations of our study should be pointed out. First, clinical remission was assessed through the long forms of the SAPS and the SANS, and no external validation of remission was used. The validity of assessing clinical remission of schizophrenia using standardized questionnaires is not completely established. Clinical judgment might still be crucial to establish remission. Because our purpose was to derive a shorter, easier instrument, we used the long forms as the standard criterion for the validity of the SF. Additional research on the validity of the SF in relation to clinical judgment is therefore necessary. In addition, our results are based on Spanish outpatients participating in a clinical trial. Therefore, more studies are necessary in a clinical practice setting of wider geographical areas.
Despite these limitations, we have shown that the SFs accurately identify remitted schizophrenia outpatients when compared with the longer, standard forms. In our paper, the definition of remission was based on the accepted consensus of at least 6 months of only mild or no symptoms. With this definition as the gold standard, an overall SF score higher than 16, maintained during at least 6 months, provides total certainty about the lack of remission. However, almost one-half of the patients classified as remitted with the overall SF score would not be classified as such, had the standard forms been used. These erroneous remitted patients (false positives) should be more carefully studied (for instance, by administering the standard longer forms, especially when there is any clinical suspicion about lack of remission regardless of an overall SF score of £16). A cut-off point of 8 for this score provides a good agreement with the longer forms for identifying remission.
Our data suggests that both conceptually and practically the SF makes sense and efficiently captures the information provided by the standard SAPS and SANS. When using the SF in clinical practice, we recommend minimizing the false positives (in this case, those falsely identified as remitted by the SF but who would have been classified as not in remission, having then been administered the standard scales). Therefore, we recommend considering the lower cut-off point (that is, 8 points). This cut-off provides a reasonable balance between sensitivity and specificity. Considering patients with a score of 8 or lower for 6 months or more in remission would be associated with a low probability of error. Nevertheless, when in doubt, the standard forms and (or) further clinical assessment are in order.
To the best of our knowledge, this is the first time that the relation between standard and short forms of the SAPS and SANS were evaluated to identify clinical remission. It is important to note that correlations between both forms of the SAPS and the SANS with the CGI were not higher than moderate (r about 0.5). It has been pointed out that there are too many threats to the CGI for it to be considered a gold standard. 9, 10 The SFs of the SAPS and the SANS should be useful for evaluating remission in clinical practice. Its brevity, simplicity of scoring, and clarity of interpretation might help clinicians in supporting their clinical wisdom with such a formal measure of remission. While an initial effort might be necessary for the clinicians to become familiar with the instrument administration and interpretation, it has an important potential that might help improve patient-doctor communication, documenting the clinical encounter, and the medical decision process. 
